| Having trouble reading this newsletter? Click here to see it in your browser. You are receiving this newsletter because you signed up from our web site. Click here to unsubscribe. |
 7 April 2009  |
 |
|
Dealmakers Newsletter Update: M&A continues at paceSponsored this month by: Never Before Has Partnering and Licensing Been So Important The 2009 BIO International Convention travels to Atlanta, Georgia, May 18–21, 2009. Join 20,000 executives, investors, scientists, researchers, policy makers and journalists from around the world for strategic discussions on new business models and new opportunities in biotech. Access the expert knowledge and resources you need to meet the challenges of today’s dynamic economy and to strengthen your business for tomorrow. Come together with the industry to explore collaborations that will deliver on the promise of biotech to heal, fuel, feed the world. Registration and Housing Now Open. http://convention.bio.org
Editor's cornerPartnering and M&A deals to continue to dominate the news as companies seek to raise funds and shore up pipelines. We have introduced our new Scorecard Index feature that allows you to track the number of deals announced every month, using several subcategories:
You can keep track of deal announcements number using our Scorecard Index - bookmark for future reference. In addition, our industry round-up and in the news sections below provide additional updates on partnering and M&A activity. April also continues the spring 'partnering event' season, with numerous events including BioWindhover, EuroMedTech, EuroPLX, EuroBiotechForum in quick succession, followed by arguably the biggest partnering event of them all: BIO2009 Convention Business Forum. These are the places where deals will be done this spring, so if you are seeking partners get yourself booked in now - details of each event below. We have recently published a new report titled Option & Evaluation Agreements in Pharma and Biotech providing detailed understanding and analysis of how and why companies enter option and evaluation deals, plus access to actual option and evaluation agreements. Finally we have updated our M&A report to reflect this latest activity, incorporating deals up to and including end 2008 - more details below. In addition, we have updated our co-promotion/co-marketing report. These join our ever expanding list of titles. We will be publishing a number of new titles shortly - watch this space! All for now -- Steve Poile -- NEW: ScorecardLaunched this month is our new overview of partnering and M&A deals - Scorecard Index. Updated monthly - we will be updating our Scorecard Index - tracking partnering and M&A deals announced every month. In additon, we track the leading deals by value in the currect year, plus a compendium of top deals by value since 2000 - view details at Scorecard.
In the news2009 continues to be domintaed with significant M&A announcements:
Other deals of note so far in April 2009:
Keep posted on the latest deals and alliances with CurrentPartnering's In the news feature Partnering roundupWith M&A the primary topic for bigpharma recently, a number of rumours have emerged about numerous bigpharma's entry into the fray:
Meanwhile several bigpharma companies have been aligning themselves as partner of choice by making their interests known and selling themselves are the ideal partner:
But not everyone is desperate to consolidate: However, M&A and the current economic climate has its side effects:
Potential new sources of funding come available: Finally, how do you measure up? Bigpharma CEO pay revealed: New and updated reportsNew report titles: CurrentPartnering has published a new title: Option & Evaluation Agreements in Pharma and Biotech The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies Royalty Financing Agreements in Pharma, Biotech and Diagnostics The Royalty Financing Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals. Revised and updated reports: CurrentPartnering has revised and updated its most popular reports: Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition The Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 2nd edition The Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 2nd edition
New from Datamonitor:
Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines Best practice articlesMerck & Schering Plough: Mega-merger that is greater than sum of its parts As a standalone company, Merck & Co. faces a tough future of declining sales. Datamonitor forecasts that the proposed merger with Schering-Plough will succeed in returning Merck to a positive sales growth outlook read more EuroPLX Enters 15th Great Year of Facilitating Pharma Deals Biosimilars in the EU: delivering the goods? Pfizer & Wyeth: opening the door for Big Pharma M&A Online webcast: A better way to conduct alliance management An exclusive webcast that brings together alliance managers to share their experiences in building and maintaining successful partnerships Listen now
Read all our partnering best practice articles. Forthcoming eventsHere are some of our suggested events for spring 2009: BIO-Windhover 2009 New York, USA - April 13-15, 2009 - more details Pharmaceutical Strategic Outlook 2009 The Grand Hyatt New York City, USA - April 13-15, 2009 - more details CHI Alliance Management Congress Boston, MA, USA - April 22-23, 2009 - more details BIO International Convention 2009 Atlanta, GA, USA, May 18-21, 2009 - more details EuroMedtech Dusseldorf, Germany, June 3-4, 2009 - more details EuroPLX 40 Warsaw Warsaw, Poland, June 8-9, 2009 - more details Euro-Biotech Forum 2009 Barcelona, Spain, June 30 to July 1, 2009 - more details People on the moveThe following people have been reported on the move during March/April 2009: Paul Clewlow, Ramani Varanasi, Jason Levin, Andrew Mills, Eric Risser to name just a few read more about the latest people on the move If you have news about a business development executive who is on the move - let us know Partnering resourcesCurrent Partnering maintains and regularly updates this list of useful resources for dealmakers across all industries. The following topic areas are available - updated regularly:
Missing something? Let us know and we will include all appropriate resources.
Contact usSteve Poile, Editor Web: http://www.CurrentPartnering.com Mail: CurrentPartnering, Allanmere House, 6 Hobgate, York, YO24 4HF, United Kingdom Tel: +44 7896 656732 Fax: +44 8703 305993
Advertizing and sponsorshipCurrentPartnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online. or contact us to discuss your requirements.
About CurrentPartneringCurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers
|
|
|
|
Sponsored by: 
CurrentPartnering reports
|
|
|
||
|
 |
|